Allogene Therapeutics (ALLO) AI Stock Analysis

• Market Cap: $236.23M
• Dividend Yield: N/A
• Average Volume (3M): 4.04M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.13
• Revenue Growth: -100.00%
• EPS Growth: 31.43%
• Country: US
• Employees: 226
• Sector: Healthcare
• Sector Strength: 39
• Industry: Biotechnology
• EPS (TTM): -0.28
• Shares Outstanding: 218,730,800
• 10 Day Avg. Volume: 5,846,483
• 30 Day Avg. Volume: 4,035,088
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 0.52
• Enterprise Value/Revenue: -5.60K
• Enterprise Value/Gross Profit: -38.14
• Enterprise Value/Ebitda: -0.52
• 1Y Price Target: $8.44
• Price Target Upside: 667.27% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 14

• Rating: 43 Neutral
• Price Target: $1.00 ▼(-9.09%Downside)

Allogene Therapeutics' overall score is driven by significant financial challenges and weak technical indicators. The company's inability to generate positive earnings and the negative sentiment from recent corporate events further weigh on the score. However, some optimism is derived from the extended cash runway and progress in clinical trials, which could potentially mitigate some risks in the future.

Positive Factors

Clinical Trial Progress

Allogene is executing on ALPHA3 with nearly 50 US sites active and an ex-US expansion planned.

Patient Participation

Enthusiasm is still high with patient consents accelerating, and numbers are expected to 'hockey stick' through YE.

Negative Factors

Regimen Change Impact

The decision to proceed without ALLO-647 in the lymphodepletion regimen raises concerns about cema-cel’s effectiveness.

Safety Concerns

Allogene dropped the FCA lymphodepletion arm in ALPHA3 due to a grade 5 adenovirus infection, resulting in the patient's death.

Allogene Therapeutics Business Overview & Revenue Model

Company Description

Allogene Therapeutics, Inc. (ALLO) is a biotechnology company focused on pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T) therapies for cancer treatment. The company operates within the healthcare sector, specifically in the field of cell therapy, and its core products involve the development of novel, off-the-shelf cell therapies designed to treat a range of hematologic malignancies and solid tumors.

How the Company Makes Money

Allogene Therapeutics makes money primarily through the development and commercialization of its proprietary AlloCAR T cell therapies. The company generates revenue through collaboration agreements, licensing deals, and strategic partnerships with other pharmaceutical companies. These relationships often involve upfront payments, milestone payments based on the achievement of clinical and regulatory goals, and royalties from potential future sales. Additionally, Allogene may engage in funding opportunities such as public offerings or private placements to support its research and development initiatives. The company's success is largely dependent on the progression of its clinical trials and the eventual approval and commercialization of its therapies.

Allogene Therapeutics Financial Statement Overview

Summary

Allogene Therapeutics faces significant financial challenges, with declining revenues, persistent losses, and dependence on external funding. While the balance sheet shows some resilience with cash reserves and moderate leverage, the lack of profitability and cash flow growth indicates the company must address operational inefficiencies to achieve sustainable growth.

Income Statement

Allogene Therapeutics has struggled to generate revenue, with a sharp decline from $38.5M in 2021 to negligible amounts in 2023 and 2024. Consistently negative EBIT and net income reflect ongoing operational challenges. The lack of revenue growth and persistent losses highlight significant financial hurdles.

Balance Sheet

The company maintains a relatively low debt-to-equity ratio, indicating moderate leverage. However, a declining equity base from $1.08B in 2020 to $422M in 2024 signals potential financial strain. The substantial cash reserves provide a buffer, but the shrinking equity ratio raises concerns about long-term stability.

Cash Flow

Negative operating and free cash flows indicate poor cash generation from operations. While financing activities have bolstered cash levels, the reliance on external funding to sustain operations could pose risks. The absence of positive cash flow growth further underscores operational inefficiencies.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	22.00K	95.00K	156.00K	114.09M	0.00
Gross Profit	-192.28M	95.00K	-256.23M	-106.09M	-11.54M
EBITDA	-243.33M	-313.07M	-321.24M	-169.74M	-250.81M
Net Income	-257.59M	-327.26M	-340.41M	-182.05M	-250.22M
Balance Sheet
Total Assets	548.71M	642.84M	817.08M	1.04B	1.23B
Cash, Cash Equivalents and Short-Term Investments	292.48M	448.70M	576.47M	809.48M	1.03B
Total Debt	90.76M	95.12M	95.12M	69.93M	53.78M
Total Liabilities	126.53M	130.60M	151.21M	122.23M	148.21M
Stockholders Equity	422.18M	512.23M	665.87M	916.41M	1.08B
Cash Flow
Free Cash Flow	-200.99M	-239.25M	-225.71M	-206.26M	-181.05M
Operating Cash Flow	-200.30M	-237.73M	-220.52M	-184.81M	-115.09M
Investing Cash Flow	75.69M	163.29M	106.16M	163.66M	-505.12M
Financing Cash Flow	116.67M	95.69M	2.95M	11.96M	633.59M

Allogene Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.10
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ALLO, the sentiment is Negative. The current price of 1.1 is below the 20-day moving average (MA) of 1.31, below the 50-day MA of 1.27, and below the 200-day MA of 1.79, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 38.06 is Neutral, neither overbought nor oversold. The STOCH value of 9.40 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ALLO.

Allogene Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CMPX	60 Neutral	$407.93M	―	-41.31%	―	―	-7.93%
ZBIO	58 Neutral	$644.66M	―	-115.47%	―	―	―
AUTL	54 Neutral	$625.43M	―	-49.91%	―	-14.16%	25.88%
Sector *	52 Neutral	kr6.05B	8.94	-56.17%	2.10%	25.95%	22.55%
ALLO	43 Neutral	$236.23M	―	-59.60%	―	-100.00%	31.43%
ANNX	38 Underperform	$268.80M	―	-66.13%	―	―	43.21%
SANA	33 Underperform	$881.92M	―	-71.44%	―	―	19.94%

Allogene Therapeutics Corporate Events

Allogene Therapeutics Adjusts ALPHA3 Trial After Adverse Event

On August 1, 2025, Allogene Therapeutics announced the selection of standard fludarabine and cyclophosphamide as the lymphodepletion regimen for its ALPHA3 study, following a Grade 5 adverse event linked to ALLO-647. The decision to close the arm testing FC plus ALLO-647 was made after consultation with the FDA and the DSMB due to severe viral infections attributed to immunosuppression from ALLO-647. The amended ALPHA3 trial will now proceed with two arms, comparing cema-cel after standard FC lymphodepletion to observation, with the next milestone being a futility analysis expected in the first half of 2026. The company will focus on advancing its AlloCAR T product candidates using the Dagger® Platform Technology, which aims to reduce the need for standard lymphodepletion.

The most recent analyst rating on (ALLO) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Allogene Therapeutics stock, see the ALLO Stock Forecast page.

Allogene Therapeutics Holds Annual Stockholder Meeting

On June 18, 2025, Allogene Therapeutics held its Annual Meeting of Stockholders, where key decisions were made. Stockholders elected three Class I Directors to serve until 2028, approved executive compensation on an advisory basis, and ratified Ernst & Young LLP as the independent accounting firm for 2025.

The most recent analyst rating on (ALLO) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Allogene Therapeutics stock, see the ALLO Stock Forecast page.